Victoza revenue trends
In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner, which reflected a ~25% YoY (year-over-year) growth in local currency.
In 4Q17 in the US and European markets, Victoza reported revenues of 4.7 billion Danish kroner and 913 million Danish kroner, respectively. That’s a ~30% and ~7% YoY growth, respectively, in local currency.
In 4Q17 in AAMEO (Asia, Africa, the Middle East, and Oceania), China, Japan and Korea, and Latin America, Victoza generated revenues of 189 million Danish kroner, 97 million Danish kroner, 158 million Danish kroner, and 141 million Danish kroner, respectively. That was an ~8%, ~68%, ~4%, and ~8% YoY growth, respectively, in local currency.
Victoza’s 2017 revenue trends
In fiscal 2017, Victoza generated revenues of 23.2 billion Danish kroner, which reflected an ~18% YoY growth in local currency.
In 2017 in the United States, Europe, AAMEO, China, and Latin America, Victoza reported revenues of 16.9 billion Danish kroner, 3.5 Danish kroner, 858 million Danish kroner, 309 million Danish kroner, and 500 million Danish kroner, respectively. That’s a ~22%, ~3%, ~22%, 24%, and 13% YoY growth, respectively, in local currency.
The overall growth in the US GLP-1 (glucagon-like peptide-1) agonist drugs market primarily propelled Victoza’s revenue growth in the US market where it had a 23% volume growth.
In December 2017, Novo Nordisk completed its Phase 3b trial on Victoza dose escalation in the Japanese population with Type 2 diabetes whose HbA1c levels could not be controlled with Victoza 0.9 mg (milligrams). It escalated the Victoza dose to 1.8 mg. After completion of the Phase 3b trial, individuals on Victoza 1.8 mg demonstrated a statistically significant lowering of their HbA1c levels compared to the 0.9 mg dose.
The label expansion of Victoza could further boost the drug’s revenue growth.